Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Gains from Sales and Divestitures (2018)

Spyre Therapeutics (SYRE) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $21645.0 as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Gains from Sales and Divestitures changed N/A year-over-year to $21645.0, compared with a TTM value of $21645.0 through Dec 2018, changed N/A, and an annual FY2018 reading of $21645.0, changed N/A over the prior year.
  • Gains from Sales and Divestitures was $21645.0 for Q4 2018 at Spyre Therapeutics, down from $32588.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $32588.0 in Q4 2015 and bottomed at $21645.0 in Q4 2018.